Drug Trial Radar · NCT06947291
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Jun 4, 2025
Primary completion
Apr 30, 2027
Study completion Oct 30, 2027
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (proof-of-concept study). Among them, Stage 2 adopts a randomized, controlled, open-label, and multicenter design.
Conditions
- Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Interventions
Glumetinib TabletsDrug
glumetinib once daily once daily under fasting conditions in each 21-day treatment cycle.
Docetaxel for Injection (Albumin-bound)Drug
Docetaxel for Injection (Albumin-bound) by intravenous injection in each 21-day treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose escalation and cohort expansion phase: The occurrence and frequency of DLT (Dose-Limiting Toxicity)Time frame: Up to approximately 24 months after the first patient is enrolled
- Dose escalation and cohort expansion phase: the occurrence and frequency of AE (Adverse Events) and SAE (Serious Adverse Events) (in accordance with NCI-CTCAE 5.0)Time frame: Up to approximately 24 months after the first patient is enrolled
- Dose escalation and cohort expansion phase: Recommended Phase 2 Dose (RP2D) for the combination therapy.Time frame: Up to approximately 24 months after the first patient is enrolled
- Proof-of-concept phase: Objective Response Rate (ORR) evaluated by the Independent Review Committee (IRC) according to the RECIST 1.1 criteria.Time frame: Up to approximately 24 months after the first patient is enrolled
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.